CD7 was previously described to be aberrantly expressed on CD34+ cells in JMML31, and there are both pre-clinical data32 and early-phase clinical trials (NCT05377827) of CD7CARTs for patients with T-ALL or AML. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.